重组织型纤溶酶原激活剂静脉溶栓治疗心源性和非心源性脑梗死的疗效分析

Analysis of Curative Effect of Recombinant Tissue Type Plasminogen Activator in Treatment of Cardiac and Non-cardiac Cerebral Infarction

目的分析重组织型纤溶酶原激活剂静脉溶栓治疗心源性和非心源性脑梗死的疗效。方法选择该院自2013年8月—2016年7月期间收治的心源性脑梗死患者30例,将其设为参照组,随后选择同期入院治疗的非心源性脑梗死患者30例,将其设为观察组,最后对两组患者的治疗效果进行统计和总结。结果通过对患者不同方法治疗后,观察组治疗2 h、治疗24 h以及治疗7 d后的NIHSS评分(10.36±2.15)分、(9.94±1.66)分、(8.80±2.53)分,同参照组(9.96±2.17)分、(9.96±2.17)分、(9.72±1.27)分进行比对,组间检验后,差异无统计学意义(P>0.05)。比对并发症发生率,观察组(6.6%)同参照组(26.7%)进行比对后明显较低,组间数据经检验后,差异有统计学意义(P<0.05)。结论在心源性和非心源性脑梗死中予以重组织型纤溶酶原激活剂静脉溶栓治疗,其效果类似,但是心源性脑梗死患者溶栓后会提升并发症发生率。

Objective To analyze the curative effect of recombinant tissue type plasminogen activator in treatment of cardiac and non-cardiac cerebral infarction. Methods 30 cases of patients with cardiac cerebral infarction admitted and treated in our hospital from August 2013 to July 2016 were selected as the control group, and then 30 cases with non-cardiac cerebral infarction patients treated at the same period were selected as the observation group, and the treatment effect of the two groups was finally counted and summarized. Results After treatment, the differences in the NIHSS scores at 2 h, 24 h and 7 d after treatment between the observation group and the control group were not statistically significant[（10.36±2.15）points,（9.94±1.66）points,（8.80±2.53）points vs（9.96±2.17）points,（9.96±2.17）points,（9.72±1.27）points]（P〈0.05）, and the incidence rate of complications in the observation group were obviously lower than that in the control group（6.6% vs 26.7%）, and the difference was statistically significant（P〈0.05）. Conclusion The effect of recombinant tissue type plasminogen activator in treatment of cardiac and non-cardiac cerebral infarction is similar, but the thrombolysis of patients with cardiac cerebral infarction can improve the incidence rate of complications.